期刊文献+

利伐沙班工业化生产合成路线分析 被引量:6

Analysis on the Synthesis of Rivaroxaban
下载PDF
导出
摘要 目的研究利伐沙班合成工艺,提高利伐沙班的合成产率,得到适合利伐沙班工业化的合成路线。方法通过查阅文献和专利,筛选出合成各关键中间体最优路线。结果与结论得到一条适用于工业化合成利伐沙班的路线。该法工艺简单,易于分离,适于工业化生产。 Objective To study on the synthesis of rivaroxaban to increase synthesis yield of rivaroxaban and find a route of industrial-ization for the synthetic of rivaroxaban. Methods The key intermediate for synthesis by screening out the optimal route from consulting literature and patents. Results and conclusion A route for the industrial synthesis of rivaroxaban was found. The method has the ad-vantages of simple process, easy separation, and is suitable for industrialized production.
出处 《中国药业》 CAS 2015年第21期4-8,共5页 China Pharmaceuticals
关键词 利伐沙班 中间体 工业化路线 rivaroxaban intermediates industrialization route
  • 相关文献

参考文献15

  • 1C·托马斯,M·贝尔韦,A·施特劳布.制备4-(4-氨基苯基)-3-吗啉酮的方法:中国,1852902[P].CN:1852902,2006-10-25.
  • 2D·多尔施,B·切赞尼,W·梅德尔斯基,等.N-芳基吗啉酮的制备方法:中国,1832933[P].2006-09-13.
  • 3Michael P. Gulseth,Jessica Michaud,Edith A. Nutescu.Rivaroxaban: An oral direct inhibitor of factor Xa[J]. American Journal of Health-System Pharmacy . 2008 (16)
  • 4Volker Laux,Elisabeth Perzborn,Dagmar Kubitza,Frank Misselwitz.Preclinical and Clinical Characteristics of Rivaroxaban: A Novel, Oral, Direct Factor Xa Inhibitor[J]. Semin Thromb Hemost . 2007 (05)
  • 5Gutcait Alexander,Wang Kuang-Chao,Liu Hsiu-Wen,Chern Ji-Wang.Studies on quinazolines. 6. Asymmetric synthesis of (S)-(+)- and (R)-(?)-3-[[4-(2-methoxyphenyl)piperazin-1-yl]methyl]-5-methylthio-2,3-dihydroimidazo[1,2-c]quinazolines[J]. Tetrahedron: Asymmetry . 1996 (6)
  • 6DIETER D,WERNER M,CHRISTOST,et al.Phenyl deriva-tives. WO,2002057236 . 2002
  • 7GLICKMAN SA,SCHULTZ HS,et al.Preparation ofN-substituted-3-morpholones. US,3092630 . 1963
  • 8Rajesh T,Madhusudhan G,Mukkanti K.A new and concise synthetic route to enantiopure Linezolid from (S)-epichlorohydrin. Der Pharma Chemica . 2011
  • 9Mederski Werner W K R,Cezanne Bertram,van Amsterdam Christoph,Bühring Karl-Ulrich,Dorsch Dieter,Gleitz Johannes,M?rz Joachim,Tsaklakidis Christos.Chlorothiophenecarboxamides as P1 surrogates of inhibitors of blood coagulation factor Xa. Bioorganic and Medicinal Chemistry . 2004
  • 10Lassen Michael R,Ageno Walter,Borris Lars C,Lieberman Jay R,Rosencher Nadia,Bandel Tiemo J,Misselwitz Frank,Turpie Alexander G G.Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. The New England Quarterly . 2008

共引文献1

同被引文献37

  • 1吴丹,王静,王艳,刘龙.噁唑烷酮类化合物的合成及其凝血因子Ⅹa抑制活性研究[J].中国药物化学杂志,2019,29(6):426-432. 被引量:1
  • 2陈华云(综述),王学锋(审校),王鸿利(审校).新型抗凝药物[J].国际输血及血液学杂志,2007,30(6):513-516. 被引量:2
  • 3LAUXV,PERZHORME,KUBITZAD,etal.Preclinicalandclinicalofrivaroxaban:anovel,oral,directfactorXainhibitor[J].SeminThrombHemost,2007,33(5):515-523.
  • 4ESCOLARG,VILLALTAJ,CASALSF,etal.Rivaroxaban:factorXainhibitoranticoagulant[J].DrugsFuture,2006,31(6):484-493.
  • 5ALEXANDERW.AmericanHeartAssociation2010ScientificSessionsandAmericanSocietyofNephrology:RenalWeek2010:43rdAnnualMeeting&ScientificExposition[J].PT,2011,36(1):46-47.
  • 6WALSHDA,FRANZYSHENSK,YANNIJM.Synthesisandantiallergyactivityof4-(diarylhydroxymethyl)-1-[3-(aryloxy)propyl]piperidinesandstructurallyrelatedcompounds[J].JMedChem,1989,32(1):105-118.
  • 7ROEHRIGS,STRAUBA,POHLMANNJ,etal.Discoveryofthenovelantithromboticagent5-chloro-N -({(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide(BAY59-7939):anoral,directfactorXainhibitor[J].JMedChem,2005,48(19):5900-5908.
  • 8柯永胜.新型抗凝药物直接Xa因子抑制剂利伐沙班[J].中国临床药理学与治疗学,2009,14(4):361-367. 被引量:28
  • 9陈怡琳,施仲伟.抗凝新药利伐沙班临床研究进展[J].心血管病学进展,2009,30(5):810-813. 被引量:30
  • 10徐佳骏,黄赛杰,苏克剑.新型口服抗凝药利伐沙班[J].医药导报,2009,28(11):1474-1476. 被引量:10

引证文献6

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部